GHENT, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.

比利时根特-（商业线）-Agomab Therapeutics NV（'Agomab'）是一家开发具有纤维化疾病疾病疾病缓解潜力的差异化项目的公司，今天宣布任命Angelika Jahreis，医学博士，博士为独立Agomab董事会非执行董事，而AndreaSáez博士，将加入Agomab的执行领导团队作为首席开发官。

As part of the next growth phase of the company, Paolo Michieli, PhD, (Founder and formerly Chief Scientific Officer) and Torsten Dreier, PhD, (previously Chief Development Officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB)..

作为公司下一个发展阶段的一部分，Paolo Michieli博士（创始人兼前首席科学官）和Torsten Dreier博士（前首席开发官）将继续在Agomab担任高级顾问和科学顾问成员董事会（SAB）。。

“Angelika’s extensive experience and deep knowledge as a senior drug developer will be of great value to the Board and our company. Additionally, our new CDO Andrea has been a driving force in the development of our clinical pipeline, and I very much look forward to working with her as part of the executive leadership team,” said Tim Knotnerus, Chief Executive Officer at Agomab Therapeutics.

“Angelika作为高级药物开发商的丰富经验和深刻知识将对董事会和我们的公司具有重要价值。此外，我们新的CDO Andrea一直是我们临床渠道发展的推动力，我非常期待与她一起工作，作为执行领导团队的一员，“蒂姆·克诺内鲁斯说，Agomab Therapeutics的首席执行官。

“Paolo and Torsten have been key figures in the early phases of the company’s formation as well as its progress to date, and I look forward to working with them both in their new roles as senior advisors and members of the SAB.”.

“Paolo和Torsten在公司成立的早期阶段以及迄今为止的进展中一直是关键人物，我期待与他们一起担任高级顾问和SAB成员的新角色。”。

“Agomab is building a leading company in the field of fibrotic diseases thanks to their innovative programs targeting ALK5 and MET,” said Angelika Jahreis, non-executive director at Agomab Therapeutics. “Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis are areas of very high unmet medical need and with significant pharma interest.”.

Agomab Therapeutics非执行董事Angelika Jahreis说：“由于针对ALK5和MET的创新计划，Agomab正在纤维化疾病领域建立一家领先公司。“纤维化克罗恩病和特发性肺纤维化是非常高的未满足的医疗需求和重大的药物兴趣领域。”。

Andrea Sáez, Chief Development Officer at Agomab Therapeutics, added: “Joining the executive team at this exciting moment of company growth enables me to continue to contribute to the progress of Agomab’s broader pipeline on our trajectory toward serving patients in high need of novel therapies.”

Agomab Therapeutics的首席开发官AndreaSáez补充说：“在公司成长的这个激动人心的时刻加入执行团队，使我能够继续为Agomab在为急需新疗法的患者服务方面的更广泛发展方向做出贡献。”

Angelika Jahreis is a purpose-driven physician scientist with over 20 years of drug development expertise at Novartis, Gilead, Genentech and Amgen, currently serving as SVP, Development Unit Head of Immunology at Novartis. She earned her MD/PhD from the University of Freiburg, Germany, conducted her postdoctoral research at The Scripps Research Institute in La Jolla and has been honored to serve as a panel member at the FDA JIA Registry and Osteoarthritis Drug Development Workshops..

Angelika Jahreis是一位由目的驱动的医师科学家，在诺华，吉利德，基因泰克和安进拥有20多年的药物开发专业知识，目前担任诺华免疫学发展部门负责人SVP。她获得了德国弗莱堡大学的医学博士学位，在拉霍亚的斯克里普斯研究所进行了博士后研究，并被授予FDA JIA注册和骨关节炎药物开发研讨会的小组成员。。

Andrea Sáez was COO/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages. Following the acquisition of Origo by Agomab in late 2021, she was Head of Portfolio at Agomab and led the development of AGMB-129 into Phase 2 trials. Andrea initiated her academic career with a PhD in Immunology at the Pompeu Fabra University followed by postdoctoral research at Vall d’Hebron Hospital where she published on the therapeutic benefit of TGF-ß inhibitors in cancer.

AndreaSáez是Origo Biopharma的COO/CSO，她在临床前和早期临床阶段领导ALK5抑制剂计划的开发。在2021年底被Agomab收购Origo之后，她担任Agomab的投资组合负责人，并领导AGMB-129的开发进入第二阶段试验。安德烈（Andrea）在庞培·法布拉大学（Pompeu Fabra University）获得免疫学博士学位，随后在瓦尔德希伯伦医院（Vall d'Hebron Hospital）进行博士后研究，在那里她发表了TGF-β抑制剂在癌症中的治疗益处。

She gained deep understanding of regulatory affairs through supporting various biotechs in CMC, preclinical and clinical regulatory topics in her role as Regulatory Affairs Manager at a leading consultancy firm, after which she became R&D Director at Pangaea Oncology. Prior to joining Origo Biopharma, Andrea was a Senior Associate at Asabys Partners, supporting several biotech investments, including the investment in Origo..

通过支持CMC的各种生物技术，作为领先咨询公司的监管事务经理的临床前和临床监管主题，她获得了对监管事务的深刻理解，之后她成为Pangaea Oncology的研发总监。在加入Origo Biopharma之前，Andrea是Asabys合作伙伴的高级助理，支持多项生物技术投资，包括对Origo的投资。。

About Agomab

关于Agomab

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in fibrotic diseases..

Agomab正在将生长因子生物学的深刻专业知识转化为先驱并开发旨在解决纤维化，修复组织结构和恢复器官功能的新型治疗方法。将新的科学见解与强大的药物开发和长期的企业愿景相结合，我们正在建立一个广泛的差异化项目临床渠道，在纤维化疾病中具有改善疾病的潜力。。